AGIOS PHARMACEUTICALS, INC.
AGIOUnited States
43 filed reports · 459 financial concepts · 12 earnings calls
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
43 reports · Sep 2015 to Sep 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 12 earnings-release figures, 32 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 5,251 | Sep 2015 to Sep 2026 |
| Annual · 10-KSEC EDGAR | 10 | 4,298 | Dec 2015 to Dec 2025 |
| Current · 8-KSEC EDGAR | 2 | 13 | Jun 2026 to Sep 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q3 | 10-Q | 2026-09-30 | 2026-11-05 | 387 | Open |
| FY2026 Q3 | 8-K | 2026-09-30 | 2026-11-05 | 12 | Open |
| FY2026 Q2 | 10-Q | 2026-06-30 | 2026-07-30 | 212 | Open |
| FY2026 Q2 | 8-K | 2026-06-30 | 2026-07-30 | 1 | Open |
| FY2026 Q1 | 10-Q | 2026-03-31 | 2026-04-29 | 212 | Open |
| FY2025 | 10-K | 2025-12-31 | 2026-02-12 | 778 | Open |
| FY2025 Q3 | 10-Q | 2025-09-30 | 2025-10-30 | 184 | Open |
| FY2025 Q2 | 10-Q | 2025-06-30 | 2025-07-31 | 153 | Open |
| FY2025 Q1 | 10-Q | 2025-03-31 | 2025-05-01 | 159 | Open |
| FY2024 | 10-K | 2024-12-31 | 2025-02-13 | 406 | Open |
| FY2024 Q3 | 10-Q | 2024-09-30 | 2024-10-31 | 163 | Open |
| FY2024 Q2 | 10-Q | 2024-06-30 | 2024-08-01 | 143 | Open |
Financial data
459 concepts · 9,562 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial438 concepts · 9,180 facts · Dec 2011 to Sep 2026
- Operating income loss64 · Dec 2013 to Sep 2026
- Allocated share based compensation expense62 · Dec 2013 to Sep 2026
- Comprehensive income net of tax62 · Dec 2013 to Sep 2026
- Net income loss62 · Dec 2013 to Sep 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax62 · Dec 2013 to Sep 2026
- Research and development expense62 · Dec 2013 to Sep 2026
- Accretion amortization of discounts and premiums investments61 · Dec 2013 to Sep 2026
- Capital expenditures incurred but not yet paid61 · Dec 2013 to Sep 2026
- Increase decrease in accounts payable61 · Dec 2013 to Sep 2026
- Increase decrease in accrued liabilities and other operating liabilities61 · Dec 2013 to Sep 2026
- Increase decrease in prepaid deferred expense and other assets61 · Dec 2013 to Sep 2026
- Payments to acquire property plant and equipment61 · Dec 2013 to Sep 2026
- Share based compensation61 · Dec 2013 to Sep 2026
- Cash and cash equivalents at carrying value60 · Dec 2013 to Sep 2026
- Revenue60 · Mar 2014 to Sep 2026
- Stockholders equity (US GAAP)60 · Dec 2013 to Sep 2026
- Accounts payable current55 · Dec 2014 to Sep 2026
- Accrued liabilities current55 · Dec 2014 to Sep 2026
- Accrued professional fees current55 · Dec 2014 to Sep 2026
- Accumulated other comprehensive income loss available for sale securities adjustment net of tax55 · Dec 2014 to Sep 2026
- Additional paid in capital common stock55 · Dec 2014 to Sep 2026
- Assets55 · Dec 2014 to Sep 2026
- Assets current55 · Dec 2014 to Sep 2026
- Common stock par or stated value per share55 · Dec 2014 to Sep 2026
Product9 concepts · 257 facts · Dec 2015 to Sep 2026
- Revenue217 · Dec 2016 to Sep 2026
- Licenses15 · Mar 2018 to Dec 2018
- TIBSOVO8 · Sep 2021 to Dec 2022
- Research and development arrangement contract to perform for others compensation earned7 · Mar 2017 to Dec 2018
- Revenue recognition milestone method revenue recognized4 · Dec 2015 to Dec 2017
- License and services revenue2 · Mar 2018
- Revenue (excluding assessed tax)2 · Sep 2019 to Jun 2020
- Milestones achieved1 · Jun 2018
- Royalty income nonoperating1 · Dec 2024
Segment8 concepts · 114 facts · Dec 2022 to Sep 2026
- Revenue23 · Dec 2022 to Sep 2026
- Net income loss15 · Dec 2022 to Sep 2026
- Research and development arrangement contract to perform for others compensation earned15 · Dec 2022 to Sep 2026
- Research and development expense15 · Dec 2022 to Sep 2026
- Segment reporting other item amount15 · Dec 2022 to Sep 2026
- Selling general and administrative expense15 · Dec 2022 to Sep 2026
- Gain loss on sale of business8 · Dec 2022 to Dec 2025
- Gain on sale of contingent payments8 · Dec 2022 to Dec 2025
KPI4 concepts · 11 facts · Sep 2025 to Sep 2026
- Research and development4 · Sep 2025 to Sep 2026
- Total operating expenses4 · Sep 2025 to Sep 2026
- Accounts receivable, net2 · Dec 2025 to Sep 2026
- Prescriptions Dispensed1 · Jun 2026
Segments
371 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis11 members · 182 facts
- Product62 · Dec 2017 to Sep 2026
- Royalty26 · Dec 2017 to Dec 2024
- Collaboration Revenue Related Party20 · Dec 2017 to Sep 2022
- Collaboration Revenue Other13 · Dec 2017 to Jun 2020
- Commercialization Activity13 · Dec 2017 to Jun 2020
- Research Services13 · Dec 2017 to Jun 2020
- License And Service12 · Dec 2017 to Mar 2020
- Development Activities11 · Dec 2017 to Dec 2019
- TIBSOVO8 · Sep 2021 to Dec 2022
- Committee Participation3 · Dec 2017 to Dec 2019
- Vorasidenib1 · Dec 2024
Statement business segments1 member · 114 facts
- Reportable114 · Dec 2022 to Sep 2026
Product or serviceus-gaap:ProductOrServiceAxis13 members · 75 facts
- Collaboration Revenue Other10 · Dec 2016 to Mar 2019
- Collaboration Revenue Related Party10 · Dec 2016 to Mar 2019
- Product10 · Dec 2016 to Mar 2019
- Royalty10 · Dec 2016 to Mar 2019
- Research Services8 · Mar 2018 to Mar 2019
- Development Services7 · Mar 2017 to Dec 2018
- Committee Participations6 · Mar 2018 to Dec 2018
- Program Licenses5 · Mar 2018 to Dec 2018
- IDHIFA4 · Dec 2015 to Dec 2017
- Development Activities2 · Mar 2018 to Mar 2019
- Other Services1 · Dec 2018
- Product1 · Sep 2019
- Royalty1 · Jun 2020
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary16 claims from 1 report · Sep 2026
- Management discussion (MD&A) commentary16 claims from 1 report · Sep 2026
- Risk-factor changes106 claims from 7 reports · Dec 2016 to Dec 2024
- Risk factors504 risks from 9 annual reports · 2015 to 2024
Earnings calls
12 calls · Feb 2024 to Nov 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q32026-11-05
- FY2026 Q22026-07-30
- FY2026 Q12026-04-29
- FY2025 Q42026-02-12
- FY2025 Q32025-10-30
- FY2025 Q22025-07-30
- FY2025 Q12025-05-01
- FY2024 Q42025-02-13
- FY2024 Q32024-10-31
- FY2024 Q22024-08-01
- FY2024 Q12024-05-02
- FY2023 Q42024-02-15
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of AGIOS PHARMACEUTICALS, INC. (AGIO) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.